Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Gut dysbiosis has been associated with intestinal and extraintestinal malignancies, but whether and how carcinogenesis drives compositional shifts of the microbiome to its own benefit remains an open conundrum. Here, we show that malignant processes can cause ileal mucosa atrophy, with villous microvascular constriction associated with dominance of sympathetic over cholinergic signaling. The rapid onset of tumorigenesis induced a burst of REG3γ release by ileal cells, and transient epithelial barrier permeability that culminated in overt and long-lasting dysbiosis dominated by Gram-positive Clostridium species. Pharmacologic blockade of β-adrenergic receptors or genetic deficiency in Adrb2 gene, vancomycin, or cohousing of tumor bearers with tumor-free littermates prevented cancer-induced ileopathy, eventually slowing tumor growth kinetics. Patients with cancer harbor distinct hallmarks of this stress ileopathy dominated by Clostridium species. Hence, stress ileopathy is a corollary disease of extraintestinal malignancies requiring specific therapies. SIGNIFICANCE: Whether gut dysbiosis promotes tumorigenesis and how it controls tumor progression remain open questions. We show that 50% of transplantable extraintestinal malignancies triggered a β-adrenergic receptor-dependent ileal mucosa atrophy, associated with increased gut permeability, sustained Clostridium spp.-related dysbiosis, and cancer growth. Vancomycin or propranolol prevented cancer-associated stress ileopathy. This article is highlighted in the In This Issue feature, p. 873.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the faecal microbiota composition in these patients substantially differs from that in individuals without cancer, with the former having an over-representation of the Enterocloster genus and loss of Lachnospiraceae or Oscillospiraceae family members”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An enrichment of SGB9226 (or SGB9228, another species of Akkermansia) beyond the 4.8% threshold (in 9% of patients), which is typically caused by antibiotic resistance and thus coincides with a dominance of the immunosuppressive Enterocloster genus and Clostridium species23,25, predicted resistance to anti-PD-(L)1 antibodies41.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Distinct species included in the responder GOMS (such as Faecalibacterium SGB15346, Clostridia bacterium SGB15383 and Roseburia hominis SGB4936) had been described as being part of the healthy GOMS25”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“such as the genus Enterocloster”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SIG1 contained members belonging to the Enterocloster genus and Streptococcaceae, Veillonellaceae, and Lactobacillaceae families that were already associated with dismal prognosis and immunoresistance.”
From Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome (2024) · cites this paper as Yonekura et al., 2022
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Million, M., Tidjani Alou, M., Khelaifia, S., Bachar, D., Lagier, J.-C., Dione, N., Brah, S., Hugon, P., Lombard, V., Armougom, F., et al. (2016) · Scientific Reports · doi:10.1038/srep26051 · Cited by 204
RetractedGlycans affect DNA extraction and induce substantial differences in gut metagenomic studies
Angelakis, E., Bachar, D., Henrissat, B., Armougom, F., Audoly, G., Lagier, J.-C., Robert, C., & Raoult, D. (2016) · Scientific Reports · doi:10.1038/srep26276 · Cited by 82
RetractedModerated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationNear-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
Self-citationGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citation
Research works printed but not linked: 1
- Beghini, 2021, Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3, e65088
Cited by
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Self-citationFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526
Self-citationTargeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Self-citationCausal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study
Long, Y., Tang, L., Zhou, Y., Zhao, S., & Zhu, H. (2023) · BMC Medicine · doi:10.1186/s12916-023-02761-6 · Cited by 401
“Conversely, it has been pointed out that cancer also affects the gut microbiota in mice, which could induce gut microbiota disorders and cancer growth [2].”
BackgroundRole of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Metadata
- Authors
- Yonekura, S., Terrisse, S., Alves Costa Silva, C., Lafarge, A., Iebba, V., Ferrere, G., Goubet, A.-G., Fahrner, J.-E., Lahmar, I., Ueda, K., Mansouri, G., Pizzato, E., Ly, P., Mazzenga, M., Thelemaque, C., Fidelle, M., Jaulin, F., Cartry, J., Deloger, M., Aglave, M., Droin, N., Opolon, P., Puget, A., Mann, F., Neunlist, M., Bessard, A., Aymeric, L., Matysiak-Budnik, T., Bosq, J., Hofman, P., Duong, C. P. M., Ugolini, S., Quiniou, V., Berrard, S., Ryffel, B., Kepp, O., Kroemer, G., Routy, B., Lordello, L., Bani, M.-A., Segata, N., Yengej, F. Y., Clevers, H., Scoazec, J.-Y., Pasolli, E., Derosa, L., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- 1Gustave Roussy, ClinicObiome, Villejuif, France.
- University of Trieste (IT)
- Kurume University (JP)
- Institut Gustave Roussy (FR)
- Centre National de la Recherche Scientifique (FR)
- The Enteric Nervous System in Gut and Brain Disorders (FR)
- 12Nantes Université, The Enteric Nervous System in Gut and Brain Disorders (TENS), Institut des Maladies de l'Appareil Digestif (IMAD), Nantes, France.
- 16JBO Consultant, Paris, France.
- Université Côte d'Azur (FR)
- The University of Melbourne (AU)
- Centre d’Immunologie de Marseille-Luminy (FR)
- 20Parean Biotechnologies, Saint-Malo, France.
- Université d'Orléans (FR)
- Karolinska University Hospital (SE)
- Centre Hospitalier de l’Université de Montréal (CA)
- University of Trento (IT)
- Royal Netherlands Academy of Arts and Sciences (NL)
- Université Paris-Saclay (FR)
- University of Naples Federico II (IT)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Yonekura, Satoru
- Terrisse, Safae
- Alves Costa Silva, Carolina
- Lafarge, Antoine
- Iebba, Valerio
- Ferrere, Gladys
- Goubet, Anne-Gaëlle
- Fahrner, Jean-Eudes
- Ueda, Kousuke
- Fidelle, Marine
- Cartry, Jérôme
- Deloger, Marc
- Aglave, Marine
- Droin, Nathalie
- Opolon, Paule
- Mann, Fanny
- Neunlist, Michel
- Aymeric, Laetitia
- Bosq, Jacques
- Hofman, Paul
- Duong, Connie P.M.
- Ugolini, Sophie
- Quiniou, Valentin
- Berrard, Sylvie
- Ryffel, Bernhard
- Kepp, Oliver
- Kroemer, Guido
- Routy, Bertrand
- Lordello, Leonardo
- Bani, Mohamed-Amine
- Segata, Nicola
- Clevers, Hans
- Scoazec, Jean-Yves
- Pasolli, Edoardo
- Derosa, Lisa
- Zitvogel, Laurence
- Venue
- Cancer Discovery
- Published
- 2021-12-20
- Volume
- 12
- Issue
- 4
- Pages
- 1128-1151
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4200119638
- Cited by
- 112
- References
- 83
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 29 · 2023: 27 · 2022: 11
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion, other-oa)
- PubMed (publishedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- HAL AMU (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, other-oa)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion)
- Funders
- European Union Horizon 2020 Project Oncobiome (825410)
- RHU LUMIERE (ANR-16-RHUS-0008)
- Agence Nationale de la Recherche (19-CE15-0029-01, ANR-18-IBHU-0002)
- ERA-Net for Research on Rare Diseases (US23/CNRS UMS3655)
- High-end Foreign Expert Program in China (GDW20171100085)
- LabEx Immuno-Oncology (ANR-18-IDEX-0001)
- Fondation ARC (186738)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- beta-adrenergic receptors, ADRB2, sympathetic nervous system, cholinergic neurotransmission, Reg3γ, intestinal permeability, Clostridium, Gram-positive bacteria, gut microbiota, carcinogenesis, tumor growth, vancomycin, propranolol, cohousing
- MeSH terms
- Humans, Intestinal Mucosa, Receptors, Adrenergic, beta, Signal Transduction, Carcinogenesis, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0999
- The paper
- Yonekura, S., Terrisse, S., Alves Costa Silva, C., Lafarge, A., Iebba, V., Ferrere, G., Goubet, A.-G., Fahrner, J.-E., Lahmar, I., Ueda, K., Mansouri, G., Pizzato, E., Ly, P., Mazzenga, M., Thelemaque, C., Fidelle, M., Jaulin, F., Cartry, J., Deloger, M., . . . Zitvogel, L. (2022). Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.